CL2021000646A1 - Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa - Google Patents

Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa

Info

Publication number
CL2021000646A1
CL2021000646A1 CL2021000646A CL2021000646A CL2021000646A1 CL 2021000646 A1 CL2021000646 A1 CL 2021000646A1 CL 2021000646 A CL2021000646 A CL 2021000646A CL 2021000646 A CL2021000646 A CL 2021000646A CL 2021000646 A1 CL2021000646 A1 CL 2021000646A1
Authority
CL
Chile
Prior art keywords
glucopyranosidase
acetamido
deoxy
glycoprotein
inhibitors
Prior art date
Application number
CL2021000646A
Other languages
English (en)
Inventor
Zhili Xin
Nathan Genung
Kevin M Guckian
Jeffrey Vessels
Lei Zhang
Ryan Gianatassio
Edward Yin Shiang Lin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of CL2021000646A1 publication Critical patent/CL2021000646A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente se describen compuestos representados por las fórmulas (IA) o (IB) o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que los comprenden y métodos para prepararlos y utilizarlos. Las variables R1, R3, R4, Y1, Y2, Ar, Z y n son como se definen en la presente.
CL2021000646A 2018-09-19 2021-03-16 Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa CL2021000646A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862733484P 2018-09-19 2018-09-19
US201862750000P 2018-10-24 2018-10-24

Publications (1)

Publication Number Publication Date
CL2021000646A1 true CL2021000646A1 (es) 2021-09-03

Family

ID=68073263

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000646A CL2021000646A1 (es) 2018-09-19 2021-03-16 Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa

Country Status (21)

Country Link
US (1) US20220041586A1 (es)
EP (1) EP3853226A1 (es)
JP (1) JP2022500472A (es)
KR (1) KR20210060513A (es)
CN (1) CN113166137A (es)
AU (1) AU2019344922A1 (es)
BR (1) BR112021004739A2 (es)
CA (1) CA3113009A1 (es)
CL (1) CL2021000646A1 (es)
CO (1) CO2021004873A2 (es)
CR (1) CR20210181A (es)
IL (1) IL281514A (es)
JO (1) JOP20210036A1 (es)
MA (1) MA53648A (es)
MX (1) MX2021003232A (es)
PE (1) PE20211591A1 (es)
PH (1) PH12021550439A1 (es)
SG (1) SG11202102379XA (es)
TW (1) TW202031651A (es)
UY (1) UY38376A (es)
WO (1) WO2020061150A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188925A1 (en) * 2020-08-03 2023-06-07 Biogen MA Inc. Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor
KR102533471B1 (ko) * 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
TWI629273B (zh) 2013-02-11 2018-07-11 美商星宿藥物公司 甲基修飾酵素之調節劑、其組成物及用途
LT2970272T (lt) * 2013-03-14 2019-04-25 Merck Patent Gmbh Glikozidazės inhibitoriai
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
CN110300752A (zh) * 2016-12-16 2019-10-01 詹森药业有限公司 单环oga抑制剂化合物
CN110312716A (zh) * 2016-12-16 2019-10-08 詹森药业有限公司 双环oga抑制剂化合物
AR110747A1 (es) 2017-01-27 2019-05-02 Lilly Co Eli Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
ES2942211T3 (es) * 2018-03-14 2023-05-30 Biogen Ma Inc Inhibidores de la O-glucoproteína-2-acetamido-2-desoxi-3-D-glucopiranosidasa

Also Published As

Publication number Publication date
IL281514A (en) 2021-04-29
CN113166137A (zh) 2021-07-23
MA53648A (fr) 2021-07-28
TW202031651A (zh) 2020-09-01
AU2019344922A1 (en) 2021-03-25
CO2021004873A2 (es) 2021-07-30
US20220041586A1 (en) 2022-02-10
SG11202102379XA (en) 2021-04-29
WO2020061150A1 (en) 2020-03-26
CR20210181A (es) 2021-07-01
UY38376A (es) 2020-04-30
PE20211591A1 (es) 2021-08-18
JP2022500472A (ja) 2022-01-04
EP3853226A1 (en) 2021-07-28
PH12021550439A1 (en) 2021-11-29
JOP20210036A1 (ar) 2021-02-25
CA3113009A1 (en) 2020-03-26
MX2021003232A (es) 2021-07-16
BR112021004739A2 (pt) 2021-06-01
KR20210060513A (ko) 2021-05-26

Similar Documents

Publication Publication Date Title
DOP2018000270A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CL2017003258A1 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201800133A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20180073A7 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY35362A (es) Compuestos terapéuticos
NI201200132A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos
CU20190086A7 (es) Compuestos de heteroarilo bicíclicos 6-6 fusionados útiles como inhibidores de lats
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
UY35818A (es) Composiciones y métodos para modular los receptores x farnesoides
UY36651A (es) Compuestos antiestrogénicos
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
CL2018001067A1 (es) Compuesto piranodipiridínico.
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CL2021000973A1 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CU20220025A7 (es) Inihibidores del factor d del complemento para administración oral
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
UY38567A (es) Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
UY38498A (es) Inhibidores de o-glucoproteina-2- acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo , piperazinilo , oxazepanilo y diazepanilo
UY38934A (es) Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica
ECSP18056196A (es) Derivados de indano
EA202190707A1 (ru) Ингибиторы о-гликопротеин-2-ацетамидо-2-деокси-3-d-глюкопиранозидазы
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria